These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2765377)

  • 1. Bone mineral content of women receiving tamoxifen for mastalgia.
    Fentiman IS; Caleffi M; Rodin A; Murby B; Fogelman I
    Br J Cancer; 1989 Aug; 60(2):262-4. PubMed ID: 2765377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer.
    Gotfredsen A; Christiansen C; Palshof T
    Cancer; 1984 Feb; 53(4):853-7. PubMed ID: 6692287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
    Zidan J; Keidar Z; Basher W; Israel O
    Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind controlled trial of tamoxifen therapy for mastalgia.
    Fentiman IS; Caleffi M; Brame K; Chaudary MA; Hayward JL
    Lancet; 1986 Feb; 1(8476):287-8. PubMed ID: 2868162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial.
    Fentiman IS; Caleffi M; Hamed H; Chaudary MA
    Br J Surg; 1988 Sep; 75(9):845-6. PubMed ID: 3052691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.
    Kristensen B; Ejlertsen B; Dalgaard P; Larsen L; Holmegaard SN; Transbøl I; Mouridsen HT
    J Clin Oncol; 1994 May; 12(5):992-7. PubMed ID: 8164053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
    Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and benign breast problems.
    Fentiman IS; Powles TJ
    Lancet; 1987 Nov; 2(8567):1070-2. PubMed ID: 2889976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.
    Johansen JS; Riis BJ; Hassager C; Moen M; Jacobson J; Christiansen C
    J Clin Endocrinol Metab; 1988 Oct; 67(4):701-6. PubMed ID: 2971080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
    Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
    J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mastalgia treatment with tamoxifen].
    Ortíz-Mendoza CM; Lucas Flores MA; Domville Ede G
    Ginecol Obstet Mex; 2003 Oct; 71():502-7. PubMed ID: 15002689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral status measured by direct photon absorptiometry in institutionalized adults receiving long-term anticonvulsant therapy and multivitamin supplementation.
    Barden HS; Mazess RB; Rose PG; McAweeney W
    Calcif Tissue Int; 1980; 31(2):117-21. PubMed ID: 6770975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women.
    Mansel R; Goyal A; Nestour EL; Masini-Etévé V; O'Connell K;
    Breast Cancer Res Treat; 2007 Dec; 106(3):389-97. PubMed ID: 17351746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Errors in longitudinal measurements of bone mineral: effect of source strength in single and dual photon absorptiometry.
    Dunn WL; Kan SH; Wahner HW
    J Nucl Med; 1987 Nov; 28(11):1751-7. PubMed ID: 3668666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in mineral content and biochemical bone markers at the menopause.
    Mazzuoli G; Minisola S; Valtorta C; Antonelli R; Tabolli S; Bigi F
    Isr J Med Sci; 1985 Nov; 21(11):875-7. PubMed ID: 4077482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton?
    Lundon KM; Jayo MJ; Register TC; Dumitriu M; Grynpas MD
    Osteoporos Int; 2000; 11(9):778-89. PubMed ID: 11210841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of bone mineral content in human vertebrae and hip by dual photon absorptiometry.
    Dunn WL; Wahner HW; Riggs BL
    Radiology; 1980 Aug; 136(2):485-7. PubMed ID: 6773102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
    Moghetti P; Castello R; Zamberlan N; Rossini M; Gatti D; Negri C; Tosi F; Muggeo M; Adami S
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual photon absorptiometric measurements of bone mineral density increase with source life.
    Lindsay R; Fey C; Haboubi A
    Calcif Tissue Int; 1987 Nov; 41(5):293-4. PubMed ID: 3121152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.